Sojournix

OverviewSuggest Edit

Sojournix is a biotechnology company developing medicines for women's health and neuroendocrine disorders. The Company is currently focused on the development of SJX-653, a novel, potent, and selective neurokinin-3 antagonist as a treatment for moderate to severe vasomotor symptoms due to menopause.

TypePrivate
Founded2016
HQWaltham, MA, US
Websitesojournixpharma.com

Latest Updates

Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Sojournix Office Locations

Sojournix has an office in Waltham
Waltham, MA, US (HQ)
400 Totten Pond Rd #110
Show all (1)

Sojournix Financials and Metrics

Summary Metrics

Founding Date

2016

Sojournix total Funding

$70 m

Sojournix latest funding size

$44 m

Time since last funding

3 years ago

Sojournix investors

Sojournix's latest funding round in January 2019 was reported to be $44 m. In total, Sojournix has raised $70 m
Show all financial metrics

Sojournix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Sojournix Online and Social Media Presence

Embed Graph

Sojournix News and Updates

Sojournix to Present at Stifel 2019 Healthcare Conference

WALTHAM, Mass., Nov. 5, 2019 /PRNewswire/ -- Sojournix, a clinical stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women's health and neuroendocrine disorders, announces that Daniel Grau, Chief Executive Officer...

Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study

WALTHAM, Mass., March 23, 2019 /PRNewswire/ -- Sojournix, a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women's health and neuroendocrine disorders, today presented positive data from a...

Sojournix Announces Positive Top-Line Phase 1 Data Demonstrating Clinical Proof of Mechanism and Once-Daily (QD) Pharmacokinetics for SJX-653

WALTHAM, Mass., Feb. 13, 2019 /PRNewswire/ -- Sojournix, a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women's health and neuroendocrine disorders, today announced positive top-line data from a first-in-human...

Sojournix Frequently Asked Questions

  • When was Sojournix founded?

    Sojournix was founded in 2016.

  • Who are Sojournix competitors?

    Competitors of Sojournix include Gennev, XL-protein and Asterion.

  • Where is Sojournix headquarters?

    Sojournix headquarters is located at 400 Totten Pond Rd #110, Waltham.

  • Where are Sojournix offices?

    Sojournix has an office in Waltham.

  • How many offices does Sojournix have?

    Sojournix has 1 office.